A Late-Stage Setback for Genentech's Muscle Program
Roche's Genentech subsidiary has discontinued late-stage clinical development of a muscle-preserving drug candidate in spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD), two rare neuromuscular diseases where the drug was being tested as a potential treatment. The decision to halt trials in these genetic indications comes after the compound failed to demonstrate sufficient efficacy in populations where muscle wasting is driven by known genetic mechanisms — a finding that raises broader questions about the drug's potential across different disease contexts.
The development is significant beyond the rare disease space because Genentech is running a separate clinical trial of the same compound in obesity. In obese patients and those taking GLP-1 receptor agonists, a major concern is the loss of lean muscle mass alongside fat — a side effect that could diminish the long-term health benefits of weight loss drugs. Genentech had been exploring whether its muscle-building agent could help preserve muscle in this context, effectively positioning it as a complement to the rapidly expanding GLP-1 market.
Why the Rare Disease Data Matters for Obesity
The logic behind testing a muscle-preservation drug in obesity relies on a similar physiological premise to its use in genetic muscle diseases: in both cases, the goal is to stimulate muscle protein synthesis or reduce muscle breakdown in the face of conditions that deplete lean tissue. If the drug cannot meaningfully build or preserve muscle in patients with SMA or FSHD — where the mechanism is well-characterized and the muscle wasting is severe — skeptics will reasonably question whether it can produce clinically meaningful effects in the comparatively milder muscle loss associated with weight reduction.
The distinction matters because obesity trials often enroll patients who are healthier and have more intact muscle biology than patients with progressive genetic neuromuscular diseases. Some researchers argue this could actually favor the drug in the obesity context — the muscle preservation target is lower and the biological environment is less hostile. But others contend that failing to move the needle in conditions defined by profound muscle loss is a discouraging indicator regardless of how the disease mechanisms differ.
The GLP-1 Muscle Problem Is Real
The question of muscle preservation alongside GLP-1-driven weight loss has become a major focus of pharmaceutical research. Studies of semaglutide and tirzepatide have consistently shown that roughly a quarter to a third of the total weight lost by patients using these drugs comes from lean mass rather than fat. For older adults and patients who are already metabolically fragile, this lean mass loss could contribute to sarcopenia, functional decline, and increased fall risk.
Several companies are developing complementary agents — primarily targeting myostatin, activin receptors, or other components of the muscle growth pathway — to address this problem. Eli Lilly, Regeneron, and a number of biotechs have active programs, and the competitive dynamics will be shaped significantly by which compounds demonstrate clinically meaningful effects in relevant patient populations.
Genentech's Strategic Position
For Roche and Genentech, the discontinuation in SMA and FSHD represents a meaningful write-down of development investment in those indications, but the bigger question is what the readout means for their obesity strategy. Roche has been investing heavily to build a GLP-1 presence and has framed combination approaches — pairing weight-loss drugs with metabolic or muscle-protective agents — as a key differentiator against Lilly and Novo Nordisk's dominant market positions.
If the muscle preservation program does not pan out in obesity trials either, it would leave a gap in Roche's proposed differentiation strategy and potentially cede even more ground to competitors who are advancing their own combo approaches. The obesity drug market is projected to exceed $150 billion annually by the early 2030s, and the stakes of the various companion therapy programs are correspondingly enormous.
SMA and FSHD Implications
Beyond the obesity narrative, the decision to halt development in SMA and FSHD is a disappointment for patients and advocacy communities in those indications. SMA has seen significant therapeutic advances with antisense oligonucleotide and gene therapy approaches, but FSHD remains without approved disease-modifying therapy, and every clinical setback in that indication delays the field's progress. Genentech has indicated it will continue the obesity trial while evaluating the implications of the rare disease data, suggesting the company has not yet concluded that the rare disease failure definitively predicts failure in the weight management context.
This article is based on reporting by endpoints.news. Read the original article.
